Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioScience Health Innovations (BHIC) Common Equity (2019 - 2026)

BioScience Health Innovations has reported Common Equity over the past 8 years, most recently at $1.7 million for Q1 2026.

  • Quarterly Common Equity rose 33.47% to $1.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Mar 2026, up 33.47% year-over-year, with the annual reading at $1.5 million for FY2025, 76.87% up from the prior year.
  • Common Equity was $1.7 million for Q1 2026 at BioScience Health Innovations, up from $1.5 million in the prior quarter.
  • Over five years, Common Equity peaked at $1.7 million in Q2 2025 and troughed at -$88990.0 in Q1 2023.
  • The 5-year median for Common Equity is $114859.0 (2024), against an average of $548576.0.
  • Year-over-year, Common Equity plummeted 65.16% in 2022 and then skyrocketed 12455.62% in 2024.
  • A 5-year view of Common Equity shows it stood at $25476.0 in 2022, then crashed by 126.53% to -$6760.0 in 2023, then skyrocketed by 12455.62% to $835240.0 in 2024, then skyrocketed by 76.87% to $1.5 million in 2025, then increased by 14.02% to $1.7 million in 2026.
  • Per Business Quant, the three most recent readings for BHIC's Common Equity are $1.7 million (Q1 2026), $1.5 million (Q4 2025), and $1.7 million (Q3 2025).